Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN Study
Bauer TM, Solomon BJ, Mazieres J, et al.
WCLC 2024
- 世界肺癌大会 2024
| 肿瘤 | 肺癌 | 博瑞纳
UK and US Patient Preferences for Tyrosine Kinase Inhibitors in ALK+ Advanced Non-Small Cell Lung Cancer in the First-Line Setting
Culver K, Montague D, Le H, et al.
WCLC 2024
- 世界肺癌大会 2024
| 肿瘤 | 肺癌 | 博瑞纳
Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
Le H, Coulter J, Culver K, et al.
WCLC 2024
- 世界肺癌大会 2024
| 肿瘤 | 肺癌 | 博瑞纳
The Cumulative Incidence of Brain Metastases in US Medicare Patients With ALK+ mNSCLC Treated With Second-Generation ALK TKIs
Bazhenova L, Abrahami D, Ramaswamy K, et al.
WCLC 2024
- 世界肺癌大会 2024
| 肿瘤 | 肺癌
